Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis

Jeong Uk Lim | Hye Seon Kang | Ah Young Shin | Chang Dong Yeo
Chan Kwon Park | Sang Haak Lee | Seung Joon Kim | Korean Association for Lung Cancer, Korea Central Cancer Registry

1Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Yeroido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bongeun St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
5Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
6Postech-Catholic Biomedical Engineering Institute, Songeui Multiplex Hall, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Correspondence
Seung Joon Kim, MD, PhD, Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Postech-Catholic Biomedical Engineering Institute, Songeui Multiplex Hall, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea.
Email: cmcksj@catholic.ac.kr

Funding information
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2020R1A2C2015140) *MSIT: Ministry of Science and ICT

Abstract
Background: Local treatment (LT) such as radiotherapy and metastasectomy on metastatic sites may improve outcomes in oligometastatic NSCLC patients, but more data are necessary to support LT in oligometastatic diseases. Patients with single extrathoracic metastatic lesion are more likely to benefit from local therapy. In this study, we evaluated the impact of LT in NSCLC patients with a single extrathoracic metastatic lesion.

Methods: Data were obtained from the Korean Association for Lung Cancer Registry (KALC-R), a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee.

Results: A total of 787 NSCLC patients with a single extrathoracic metastatic lesion were evaluated. In the multivariate analysis for OS, age, female sex, poor performance score, squamous histological subtype, LT, and initial treatment modality showed significant associations. Regarding LT, groups that underwent curative LT were significantly associated with better OS compared to groups that did not undergo LT (p = 0.011, HR 0.448, 95% CI: 0.242–0.829). In the multivariate analysis of patients who underwent LT, poor performance score, initial treatment modality, and T stage were independently associated with poor OS. Compared to the T1 stage, T3 stage showed an HR of 2.470 (95% CI: 1.309–4.663; p = 0.005) and T4 stage showed an HR of 2.063 (95% CI: 1.093–3.904; p = 0.026).

Conclusion: In NSCLC with a single extrathoracic metastatic lesion, LT, especially for curative purposes, has an independent association with OS. Moreover, among the patients who received LT, factors such as T stage, poor performance score, and initial treatment modality were significantly associated with OS.

[Correction added on 20 April 2022, after first online publication: in author byline, ‘South Korea Central Cancer Registry’ has been amended to ‘Korea Central Cancer Registry.’]
INTRODUCTION

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Among NSCLC cases, stage IV cancer comprises 35%–40% of all newly diagnosed NSCLC cases.\textsuperscript{1–3} In the past two decades, advances in targeted therapy and immunotherapy have improved clinical outcomes in stage IV NSCLC.\textsuperscript{4–10} Despite the advent of treatment modalities, the 5-year survival rate of patients with metastatic NSCLC remains poor.\textsuperscript{11}

In stage IV cancer, oligometastasis is usually used to describe patients with ≤5 extrathoracic metastatic lesions in ≤3 organs,\textsuperscript{12,13} and they comprise 20%–50% of all patients with locally advanced and metastatic NSCLC.\textsuperscript{14,15} According to Hellmann and Weichselbaum, oligometastasis is the state in which the progressing tumor cells are confined to a single or a few organs owing to the relatively limited number of seeding tumor cells and receptivity of the host organ. Furthermore, oligometastatic cancer is clinically more indolent than disseminated diseases\textsuperscript{12,16} and shows better outcomes than the more advanced disseminated stage IV cancers.\textsuperscript{17,18}

In addition to systemic treatment for NSCLC, local treatment (LT) for intrathoracic lesions and oligometastic sites can be considered in treatment of oligometastatic patients. Treatment modalities mainly include radiotherapy, and several studies have shown association with overall survival (OS) or progression-free survival (PFS) in the patient groups after radiotherapy to the metastatic sites.\textsuperscript{19–22} Nevertheless, the majority of study patients with oligometastatic diseases are heterogeneous in terms of the tumor burden and treatment modalities, and only few studies have a large number of patients enrolled. Furthermore, questions of which clinical factors are related to the benefit of LT in oligometastatic patients remain.

In terms of tumor burden, patients with a single extrathoracic distant metastasis are more likely to benefit from local therapy than patients with more metastatic lesions. Patients with multiple metastastic lesions show worse prognosis than those with a single metastatic lesion.\textsuperscript{23} In addition, a study showed that a small number of metastatic lesions was associated with a good prognosis in patients with oligometastatic/oligoprogressive NSCLC who underwent radiotherapy.\textsuperscript{24} We assume that the impact of LT is maximized in oligometastatic patients with a small number of metastatic lesions, and patients with a single distant metastatic lesion can be a good study population in which to evaluate the impact of LT.

In this study, we analyzed a nationwide database in Korea to evaluate the impact of LT in NSCLC with a single extrathoracic metastatic lesion.

METHODS

Patient selection

Data from the Korean Association for Lung Cancer Registry, a database created using a retrospective sampling survey by the Korean Central Cancer Registry (KCCR) and the Lung Cancer Registration Committee, were used for the present study.\textsuperscript{25} During 2014–2016 period, the Korean Central Cancer Registry (KCCR) registered the data of patients newly diagnosed with lung cancer (24354 patients in 2014, 24502 patients in 2015, and 25780 patients in 2016). From the eligible patients, about 10% of the overall patients that are representative of the whole population, were selected for more detailed survey after stratified random sampling. The patients with lung cancer were randomly selected from certified 13 regional cancer centers and 39 hospitals in Korea from which a significant number of registrations were made.\textsuperscript{26} Patients were stratified by the date of diagnosis, sex, age, and extent of cancer spread.\textsuperscript{25} After excluding multiple primary cancer patients, 2621 patients in 2014, 2660 patients in 2015, and 2829 patients in 2016 were selected from the 52 centers through systematic sampling methods.\textsuperscript{27} Of the 8110 patients registered between 2014 and 2016, 1059 SCLC patients were excluded, and a total of 7051 patients with NSCLC were selected. Among the selected patients, 2909 patients with stage IV cancer were enrolled in this study. According to the data on extrathoracic metastatic sites, 787 patients with a single extrathoracic metastatic lesion were finally included in the evaluation (Figure S1). All patients were confirmed as having a single site of synchronous extrathoracic metastasis at the time of diagnosis by imaging investigations according to national protocols that include routine positron emission tomography computed tomography (PET/CT), bone scan and brain magnetic resonance imaging.

Based on a standardized protocol, data on age, sex, body mass index (BMI), smoking history, results of radiological findings, Eastern Corporative Oncology Group (ECOG) performance status (PS) at the time of diagnosis, clinical stage, treatment modalities, tumor burden, metastatic sites, and survival status were collected. The registered patients were followed up until December 09, 2020.\textsuperscript{25} All the data in the study are from the registered database and no additional review of individual patient data was performed.

Statistical analysis

Continuous variables are expressed as mean ± standard deviation or median (range) values and categorical variables are expressed as percentages. Continuous variables were...
compared using the Mann–Whitney U test, and categorical variables were compared using the chi-square test. Risk factors for mortality were analyzed using the Cox proportional hazards model. Survival was analyzed using the Kaplan–Meier method and compared using log-rank tests. All \( p \)-values were two-tailed, with statistical significance set at \( p < 0.05 \). All statistical analyses were performed using the Statistical Package for the Social Sciences version 20.0 (IBM Corp.).

**Definition of LT**

In the present study, LT included local radiotherapy or metastasectomy. Local radiotherapy on both intra- and extrathoracic lesions or metastasectomy was regarded as LT. Patients were categorized according to the objectives of LT as curative or other purposes and according to the treatment site as intra- or extrathoracic. Curative intent LT include stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) to metastatic lesions; however, other radiotherapy modalities were also categorized as curative if multidisciplinary teams approved the treatment for curative purpose. In addition, metastasectomy for solitary extrathoracic metastatic lesion was categorized as curative LT. Extrathoracic sites included the bone, brain, liver, adrenal gland, extrathoracic lymph nodes, and other sites. The sites termed as “other sites” included the eye, intestine, spleen, skin, scalp, etc. Patients who underwent RT for lung parenchymal lesions were categorized as those receiving intrathoracic LT. However, concurrent intrathoracic metastatic lesions such as malignant pleural effusion or pericardial effusion were not the target of LT.

**RESULTS**

**Clinical characteristics of patients**

A total of 787 NSCLC patients with a single extrathoracic metastatic lesion were evaluated in this study. All patients were clinically diagnosed with stage IV cancer. Their mean age was 68.1, and 202 (25.7%) patients were female. Median OS was 8.8 months (95% confidence interval [CI]: 7.7–9.9 months). The mean BMI was 22.3. Adenocarcinoma accounted for the highest proportion (54.0%), followed by the squamous cell type (23.3%) and unspecified NSCLC type (8.6%). Regarding the performance data, 515 (91.3%) patients had an ECOG score of 0–2. Among the patients with \( EGFR \) mutation status data, 171 of 532 (32.1%) patients had positive \( EGFR \) mutations. A total of 218 (27.7%) patients had concurrent intrathoracic metastatic lesions: malignant pleural effusion in 123 (15.6%), malignant pericardial effusion in 20 (2.5%), pleural nodules in 50 (6.4%), and contralateral lung in 89 (11.3%). Regarding the sites of extrathoracic metastasis, bones were the most common, followed by brain.

| Table 1: Clinical characteristics of patients |
|---------------------------------------------|
| **Patients** |
| **Number** | 787 |
| **Age** | 68.1 ± 11.8 |
| **Sex (female)** | 202 (25.7) |
| **BMI** | 22.3 ± 3.4 |
| **Ever smokers** | 505 (65.1) |
| **OS (months) (median, 95% CI)** | 8.8 (7.7–9.9) |

**Pathology**

| Squamous | 183 (23.3) |
| Adenocarcinoma | 425 (54.0) |
| Large cell | 8 (1.0) |
| NSCLC NOS | 68 (8.6) |
| Other | 103 (13.1) |

**ECOG**

| 0–1 | 449 (79.6) |
| 2 or more | 115 (20.4) |

**\( EGFR \) mutation**

| 171/532 (32.1) |

**T stage (T1/T2/T3/T4)**

| 76 (11.9)/189 (29.7)/155 (24.3)/217 (34.1) |

**N stage (N0/N1/N2/N3)**

| 126 (16.7)/56 (7.4)/218 (28.9)/353 (46.9) |

**Concurrent intrathoracic metastatic lesions**

| 218 (27.7) |

**MPE**

| 123 (15.6) |

**Contralateral lung**

| 89 (11.3) |

**Pleural nodule**

| 50 (6.4) |

**Malignant pericardial effusion**

| 20 (2.5) |

**M1b, extrathoracic site**

| Bone | 330 (41.9) |
| Brain | 214 (27.2) |
| Adrenal | 76 (9.7) |
| Liver | 74 (9.4) |
| Extrathoracic LN | 67 (8.5) |
| Other sites | 30 (3.8) |

**Initial treatment**

| Chemotherapy | 292 (39.8) |
| Best supportive care | 201 (27.4) |
| Radiotherapy | 93 (12.7) |
| CCRT | 91 (12.4) |
| Surgery | 26 (3.5) |
| Unknown | 30 (4.1) |
| LT performed | 301 (38.2) |

**LT objectives (n = 301)**

| Curative | 32 (10.6) |
| Noncurative | 269 (89.4) |

**LT modality**

| Metastasectomy | 17 (2.2) |
| RT | 297 (37.7) |

Abbreviations: BMI, body mass index; CCRT, concurrent chemoradiation therapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; \( EGFR \), epidermal growth factor receptor; LN, lymph node; LT, local treatment; MPE, malignant pleural effusion; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OS, overall survival; RT, radiotherapy.
Table 2: Comparison between short- and long-term survivors (740 patients with survival data)

|                           | OS <2 years | OS >2 years | p-value |
|---------------------------|-------------|-------------|---------|
| Number                    | 578         | 162         |         |
| Age                       | 69.3 ± 11.5 | 62.1 ± 10.8 | <0.001  |
| Sex                       |             |             | <0.001  |
| Male/female               | 454 (78.5)/124 (21.5) | 101 (62.3)/61 (37.7) |         |
| Body mass index           | 22.1 ± 3.5  | 22.3 ± 3.1  | <0.001  |
| Pathology                 |             |             |         |
| Squamous                  | 170 (29.4)  | 13 (8.0)    | <0.001  |
| Adenocarcinoma            | 290 (50.2)  | 134 (82.7)  | <0.001  |
| Large cell                | 7 (1.2)     | 1 (0.6)     | 0.518   |
| NSCLC NOS                 | 56 (9.7)    | 11 (6.8)    | 0.256   |
| Other                     | 55 (9.5)    | 3 (1.9)     | 0.173   |
| ECOG                      |             |             | <0.001  |
| 0–1                       | 322 (77.0)  | 116 (93.5)  |         |
| 2 or more                 | 96 (23.0)   | 8 (6.5)     |         |
| EGFR mutation             | 92/384 (24.0) | 79/145 (54.5) | <0.001  |
| Concurrent intrathoracic  |             |             |         |
| metastatic lesion         |             |             |         |
| MPE                       | 95 (16.4)   | 25 (15.4)   | 0.759   |
| Pleural nodule            | 31 (5.4)    | 17 (10.5)   | 0.019   |
| Contralateral lung        | 57 (9.9)    | 22 (13.6)   | 0.176   |
| Malignant pericardial effusion | 18 (3.1) | 2 (1.2) | 0.192   |
| M1b, extrathoracic site   |             |             |         |
| Bone                      | 252 (43.6)  | 65 (40.1)   | 0.430   |
| Brain                     | 139 (24.0)  | 59 (36.4)   | 0.002   |
| Adrenal                   | 58 (10.0)   | 15 (9.3)    | 0.770   |
| Extrathoracic LN          | 48 (8.3)    | 16 (9.9)    | 0.529   |
| Liver                     | 57 (9.9)    | 6 (3.7)     | 0.013   |
| Other sites               | 26 (4.5)    | 3 (1.9)     | 0.125   |
| Initial treatment         |             |             | <0.001  |
| Chemotherapy              | 201 (37.2)  | 89 (60.5)   |         |
| CCRT                      | 60 (11.1)   | 30 (20.4)   |         |
| Radiotherapy              | 78 (14.4)   | 10 (6.8)    |         |
| Surgery                   | 14 (2.6)    | 11 (7.5)    |         |
| Best supportive care      | 168 (31.1)  | 5 (3.4)     |         |
| Unknown                   | 20 (3.7)    | 2 (1.4)     |         |
| LT                        |             |             | 0.001   |
| Not performed             | 367 (63.5)  | 79 (48.8)   |         |
| Performed                 | 211 (36.5)  | 83 (51.2)   |         |
| LT objectives             | (n = 211)   | (n = 83)    | 0.354   |
| Curative                  | 24 (11.4)   | 7 (8.4)     |         |
| Noncurative               | 187 (88.6)  | 76 (91.6)   |         |
| LT modality               |             |             |         |
| Metastasectomy            | 10 (1.7)    | 7 (4.3)     | 0.051   |
| RT                        | 208 (36.0)  | 82 (50.6)   | 0.001   |

Abbreviations: BMI, body mass index; CCRT, concurrent chemoradiation therapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LN, lymph node; LT, local treatment; MPE, malignant pleural effusion; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OS, overall survival; RT, radiotherapy.
There were 292 (39.8%) patients who received systemic chemotherapy as a first-line treatment, followed by the best supportive care (201 [27.4%]), radiotherapy (93 [12.7%]), and concurrent chemoradiation therapy (CCRT) (91 [12.4%]). Regarding the LT modality, 17 (2.2%) patients underwent metastasectomy and 297 (37.7%) underwent radiotherapy (Table 1).

Comparison between short- and long-term survivors

Among the 740 patients with survival data, 578 had an OS of less than 2 years and 162 had an OS longer than 2 years. Clinicopathological parameters were compared between the groups (Table 2). There were 124 (21.5%) and 61 (37.7%) female patients classified as short- and long-term survivors, and the mean age was 69.3 and 62.1 years, respectively ($p < 0.001$ and $p < 0.001$). Mean BMI was 22.1 and 22.3 in short- and long-term survivors, respectively ($p < 0.001$).

The long-term survivor group had a significantly higher proportion of adenocarcinoma cases (82.7% vs. 50.2%, $p < 0.001$) and a better PS of ECOG 0–2 (97.6% vs. 90.9%, $p = 0.014$). The proportion of EGFR mutations was higher in the long-term survivors than in the short-term survivors (54.5% vs. 24.0%, $p < 0.001$).

Regarding the concurrent intrathoracic metastatic findings, the long-term survivor group showed a higher proportion of patients with pleural nodules (10.5% vs. 5.4%, $p = 0.019$). For the extrathoracic sites, the percentage of brain metastasis was higher in the long-term survivor group (36.4% vs. 24.0%, $p = 0.002$), while the percentage of liver metastasis was significantly lower (3.7% vs. 9.9%, $p = 0.013$).

Systemic chemotherapy comprised the highest proportion among the initial treatment modalities for the long-term survivor (60.5%) and short-term survivor (37.2%) groups. In addition, the best supportive care accounted for 31.1% for the short-term survivor group, which was higher than that for the long-term survivor group (3.4%). The long-term survivor group showed a higher proportion of patients who received LT than the short-term survivor group (51.2% vs. 36.5%, $p < 0.001$). Patients who underwent LT showed significantly better OS when compared with the patients who did not ($p < 0.001$). Median OS was 6.1 months for no LT group (95% CI: 5.1–7.0 months) and 12.3 months for LT group (95% CI: 10.7–13.9 months) (Figure 1).
Various clinicopathological parameters were entered into the univariate analysis for association with OS (Table 3). In the univariate analysis, age, sex, BMI, ECOG, LT, initial treatment modality, pathologic subtypes, smoking status, metastatic site, T stage, and N stage showed significant association with OS. Factors significant in the univariate analysis were included in the multivariate analysis. Age, female sex, worse ECOG status, squamous subtype, and initial treatment modality showed a significant association. In the multivariate analysis, the group that underwent curative LT showed a significant association with better OS compared to the group that did not undergo treatment ($p = 0.011$, HR 0.448, 95% CI: 0.242–0.829). When three groups of patients who did not undergo LT, curative LT, and LT of other purposes were compared, Kaplan–Meier survival analysis showed a significant difference ($p < 0.001$). Median OS was 6.1 months for no LT group (95% CI: 5.1–7.0 months), 13.5 months for curative LT group (95% CI: 9.0–18.0 months), and 12.3 months for noncurative LT group (95% CI 10.6–14.0 months) (Figure FIGURE 1b).

### Table 3: Evaluation of clinical parameters associated with OS in patients

| Parameter                                    | Univariate |          | Multivariate |          |
|----------------------------------------------|------------|----------|--------------|----------|
|                                              | p-value    | HR (95% CI) | p-value      | HR (95% CI) |
| Age (n = 739)                                | <0.001     | 1.031 (1.024–1.038) | <0.001     | 1.022 (1.011–1.034) |
| Gender (n = 740)                             | <0.001     | 1         | 0.010        | 1         |
| BMI (n = 682)                                | <0.001     | 0.669 (0.559–0.801) | 0.629      | 0.443–0.893 |
| ECOG 01 vs. 2–4 (n = 541)                    | <0.001     | 0.936 (0.912–0.960) | 0.440      | 0.987 (0.954–1.021) |
| LT (n = 740)                                 | <0.001     | 2.033 (1.628–2.538) | <0.001     | 1.758 (1.310–2.359) |
| Initial treatment (n = 666)                  | <0.001     | 1         | <0.001      | 1         |
| Pathology (n = 740)                          | <0.001     | 1         | <0.001      | 1         |
| Never vs. ever smoker (n = 734)              | <0.001     | 1         | 0.969       | 1         |
| Metastatic site (M1b) (n = 740)               | <0.001     | 1         | 0.966 (0.568–0.781) | 0.121      | 0.767 (0.548–1.072) |
| T stage (n = 607)                            | <0.001     | 1         | 0.377       | 1         |
| N stage (n = 714)                            | <0.001     | 1         | 0.881       | 1         |

Abbreviations: BMI, body mass index; CCRT, concurrent chemoradiation therapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LN, lymph node; LT, local treatment; NSCLC, non-small cell lung cancer; OS, overall survival; RT, radiotherapy.

Evaluation of clinical parameters associated with OS in overall patients
## Table 4

Comparison between three groups according to LT status

|                      | Non-LT | Intrathoracic LT | Extrathoracic LT (on initially confirmed metastatic site at diagnosis) | p-value |
|----------------------|--------|------------------|------------------------------------------------------------------------|---------|
| Number               | 486    | 73               | 228                                                                    | <0.001b |
| Age                  | 70.2 ± 11.4 | 66.8 ± 11.2 | 64.2 ± 11.7                                                               | 0.003   |
| Sex (female)         | 124 (25.5) | 8 (11.0)   | 70 (30.7)                                                               | 0.021b  |
| BMI                  | 22.1 ± 3.35 | 22.2 ± 3.6  | 22.9 ± 3.5                                                               | 0.021b  |
| Pathology            |        |                 |                                                                        |         |
| Squamous             | 117 (24.1) | 34 (46.6)   | 32 (14.0)                                                               | <0.001  |
| Adenocarcinoma       | 240 (49.4) | 28 (38.4)   | 157 (68.9)                                                               | <0.001  |
| Large cell           | 5 (1.0)   | 1 (1.4)    | 2 (0.9)                                                                  | 0.935   |
| NSCLC NOS            | 37 (7.6)   | 8 (11.0)   | 23 (10.1)                                                                | 0.416   |
| Other                | 87 (17.9)  | 2 (2.7)    | 14 (6.1)                                                                 | <0.001  |
| ECOG                 |        |                 |                                                                        | 0.822   |
| 0–1                  | 252 (78.8) | 47 (79.7)   | 150 (81.1)                                                               |         |
| 2 or more            | 68 (21.2)  | 12 (20.3)   | 35 (18.9)                                                                |         |
| EGFR mutation        | 92/294 (31.3) | 10/51 (19.6) | 69/187 (36.9)                                                           | 0.058   |
| T stage (T1/T2/T3/T4) | 45 (11.8)/101 (26.6)/93 (24.5)/141 (37.1) | 9 (13.4)/18 (26.9)/17 (25.4)/23 (34.3) | 22 (11.6)/70 (36.8)/45 (23.7)/53 (27.9) | 0.233   |
| N stage (N0/N1/N2/N3) | 69 (14.9)/33 (7.1)/128 (27.7)/232 (50.2) | 14 (19.2)/5 (6.8)/21 (28.8)/33 (45.2) | 43 (19.7)/18 (8.3)/69 (31.7)/88 (40.4) | 0.368   |
| Concurrent intrathoracic metastatic lesion | 152 (31.3) | 9 (12.3) | 57 (25.0) | 0.002 |
| MPE                  | 86 (17.7)  | 7 (9.6)    | 30 (13.2)                                                                | 0.098   |
| Contralateral lung   | 61 (12.6)  | 3 (4.1)    | 25 (11.0)                                                                | 0.103   |
| Pleural nodule       | 34 (7.0)   | 0 (0.0)    | 16 (7.0)                                                                  | 0.065   |
| Malignant pericardial effusion | 15 (3.1) | 2 (2.7) | 3 (1.3) | 0.372 |
| M1b sites            |        |                 |                                                                        |         |
| Bone                 | 196 (40.3) | 28 (38.4)   | 106 (46.5)                                                               | 0.241   |
| Brain                | 81 (16.7)  | 16 (21.9)   | 117 (51.3)                                                               | <0.001  |
| Liver                | 68 (14.0)  | 6 (8.2)    | 0 (0.0)                                                                  | <0.001  |
| Adrenal              | 59 (12.1)  | 14 (19.2)   | 3 (1.3)                                                                  | <0.001  |
| Extrathoracic LN     | 57 (11.7)  | 9 (12.3)   | 1 (0.4)                                                                  | <0.001  |
| Other sites          | 28 (5.8)   | 0 (0.0)    | 2 (0.9)                                                                  | 0.001   |
| Initial treatment    |        |                 |                                                                        | <0.001  |
| Chemotherapy         | 218 (46.2) | 18 (28.1)   | 56 (28.4)                                                                |         |
| Best supportive care | 201 (42.6) | 0 (0.0)   | 0 (0.0)                                                                  |         |
| Radiotherapy         | 7 (1.5)    | 27 (42.2)  | 59 (29.9)                                                                |         |
| CCRT                 | 5 (1.1)    | 16 (25.0)  | 70 (35.5)                                                                |         |
| Surgery              | 11 (2.3)   | 3 (4.7)    | 12 (6.1)                                                                  |         |
| Unknown              | 30 (6.4)   | 0 (0.0)    | 0 (0.0)                                                                  |         |
| LT objectives        |        |                 |                                                                        | <0.001  |
| Curative             | 0 (0)      | 29 (39.7)  | 3 (1.3)                                                                  |         |
| Noncurative          | 0 (0)      | 44 (60.3)  | 225 (98.7)                                                               |         |
| LT modality          |        |                 |                                                                        | <0.001  |
| Metastasectomy       | 0 (0.0)    | 0 (0.0)    | 17 (7.5)                                                                  | -       |
| RT                   | 0 (0.0)    | 73 (100)   | 224 (98.2)                                                               | <0.001  |

**Abbreviations:** #A: No LT versus intrathoracic LT; B: No LT versus extrathoracic LT; C: intrathoracic LT versus extrathoracic LT. Abbreviations: BMI, body mass index; CCRT, concurrent chemoradiation therapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LN, lymph node; LT, local treatment; MPE, malignant pleural effusion; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OS, overall survival; RT, radiotherapy.
Comparison between the three groups according to the status of LT

Patients were categorized into three groups according to their LT status and target sites (Table 4). Among the patients, 486 did not receive LT, 73 received LT only on intrathoracic sites, and 228 received LT for extrathoracic lesions. Clinicopathological parameters were compared among the three groups. The non-LT group showed the highest mean age among the three groups ($p < 0.001$). The extrathoracic LT group showed the highest proportion of female patients (30.7%, $p = 0.003$), and the highest mean BMI of 22.9 ($p = 0.021$).

Regarding pathological types, the intrathoracic LT group showed the highest proportion of squamous cell type (46.6%, $p < 0.001$). There were no significant differences in ECOG, EGFR mutation, T stage, and N stage among the groups. The intrathoracic LT group showed the lowest percentage of intrathoracic metastatic lesions (12.3%, $p = 0.002$). The extrathoracic LT group showed the highest proportion of brain metastasis (51.3%, $p < 0.001$) and the
lowest percentage of extrathoracic lymph node (0.4%, \( p < 0.001 \)), adrenal gland (1.3%, \( p < 0.001 \)), and liver (0%, \( p < 0.001 \)) metastases. Among the initial treatment modalities, the extrathoracic LT group showed the highest proportion of CCRT (35.5%) and a smaller proportion of radiotherapy (29.9% vs. 42.2%) compared with the intrathoracic LT group.

As a LT modality, all metastasectomy cases \( (n = 17) \) were included in the extrathoracic LT group. In the Kaplan–Meier survival analysis, the three groups showed a statistically significant difference \( (p < 0.001) \). Median OS was 13.1 months for the intrathoracic LT group \( (95\% \text{ CI}: 10.0–16.2 \text{ months}) \) and 11.8 months for the extrathoracic LT group \( (95\% \text{ CI}: 10.0–13.6 \text{ months}) \) (Figure 1c).

Patients were also grouped into curative and noncurative LT groups. There were 32 patients in the curative LT group, and 269 patients in the noncurative LT group (Table S1). The curative LT group showed a significantly higher proportion of males, squamous cell cancer, and lower proportion of concurrent intrathoracic metastatic lesion, and brain metastatic lesion when compared to the noncurative LT group.

Analysis of association between clinical parameters and OS in patients who received LT \( (n = 301) \)

Table 5 shows survival analysis performed in the group that underwent LT. In the univariate analysis, age, sex, BMI, ECOG, initial treatment modality, pathology, smoking status, metastatic site, and T stage were found to be significant factors, which were then entered into the multivariate analysis. Worse ECOG, initial treatment modality, and T stage were independently associated with poor OS. Poor ECOG of 2–4 showed an HR 1.645 \( (95\% \text{ CI}: 1.076–2.524; \ p = 0.022) \) when compared to ECOG of 0–1. Compared to surgery as an initial treatment, radiotherapy showed an HR of 3.975 \( (95\% \text{ CI}: 1.375–11.494; \ p = 0.011) \) and CCRT showed an HR of 3.750 \( (95\% \text{ CI}: 1.331–10.566; \ p = 0.012) \). Compared to T1 stage, T3 stage showed an HR of 2.470 \( (95\% \text{ CI}: 1.309–4.663; \ p = 0.005) \) and T4 stage showed an HR of 2.063 \( (95\% \text{ CI}: 1.093–3.904; \ p = 0.026) \).

DISCUSSION

The present study showed that LT was independently associated with OS in NSCLC patients with a single extrathoracic metastatic lesion. Furthermore, clinical parameters such as ECOG, initial treatment modality, and T stage were predictive of OS in patients who underwent LT.

Phase II studies performed by Gomez et al.\(^{22}\) and Iyengar et al.\(^{31}\) showed that local consolidative therapy may contribute to improvement in outcomes of oligometastatic NSCLC. Other studies also proved that local therapy to metastatic sites were associated with OS and PFS in oligometastatic patients.\(^{19–22}\) Several prospective studies that evaluated efficacy of local ablative therapy and systemic treatment in oligometastatic NSCLC are reported.\(^{32–34}\) NCT 01282450 enrolled 40 pathologically proven NSCLC stage IV patients with less than five metastases at initial diagnosis, and median PFS was 12.1 months.\(^{33}\) The SINDA study \( (NCT02893332) \), a phase III randomized control trial, evaluated the efficacy of upfront concurrent first generation tyrosine kinase inhibitors (TKI) with the addition of stereotactic ablative radiotherapy (SABR) versus without SABR in synchronous oligometastatic NSCLC with \( \text{EGFR} \) mutation. The interim results showed SABR plus TKI was associated with improvement in OS and PFS when compared with TKI alone.\(^{35}\) Other ongoing studies such as SABR-Comet and “Oligomez” also showed potential clinical benefit of concurrent local radiotherapy in oligometastatic NSCLC.\(^{31,34}\) Similar to the previous studies, LT, which was comprised of mainly local radiotherapy to either intrathoracic lung lesion or extrathoracic metastatic lesion and a small number of metastasectomies, was shown to have a significant association with OS in our population. Furthermore, patients who underwent LT for curative purposes showed a significantly more favorable survival than those who did not undergo LT in the multivariate analysis. In contrast, the groups that underwent LT for other purposes were not independently associated with OS compared to the no-LT group. It was unexpected that there was no statistically significant difference in OS between noncurative and curative LT groups in the multivariate analysis. This statistical disparity suggests that patients who received curative LT may have other related positive prognostic factors that were not accounted for in the multivariate analysis, and that effect of LT itself should be elucidated in settings that are more accurate. In the present study, a sizable proportion of patients who received LT for purposes other than the curative objective received radiotherapy for palliative objectives. The patients received radiotherapy to relieve associated symptoms or reduce the disease burden of metastatic lesions. We assume that the metastatic disease burden might have been heavier in this group than in the group that underwent curative LT. In the comparison between the curative and noncurative LT groups, the curative LT group showed a significantly lower proportion of concurrent intrathoracic metastatic lesion, and we assume that it contributed to the favorable association with OS in the curative LT group. However, we believe that a further validation study with larger population is necessary to evaluate association between objective of LT and OS, since only 32 patients were allocated to the curative LT group in our study.

Previous studies have shown the clinical impact of LT in oligometastatic NSCLC, which is mostly comprised of local radiotherapy and smaller number of metastasectomies.\(^{36,37}\) However, several studies had heterogeneous populations in terms of tumor burden. The number of metastatic lesions differed among the study patients.\(^{17,38}\) In other studies, oligometastatic, oligoproggressive, and oligoresidual sites were all included.\(^{39–41}\) Thus, to more accurately assess the impact of LT, it was necessary to add homogeneity to the
The reason for the higher proportion of In the present study, the It should be taken into consideration In addition, local treatment of brain met-

Another retrospective study by Zhang to the intrathoracic lesion may have been required. which invasion of the central airway is present, radiotherapy is more likely to be centrally located, and in some cases in the frequent pathological type in the intrathoracic LT group, lesions. We assume that the squamous cell type, which was accounted for the large percentages of intrathoracic metastatic lesions. The proportion of squamous cell carcinoma was 46.6% and 14.0% in the intra- and extrathoracic LT groups, respectively. When compared to adenocarcinoma type, squamous cell carcinoma showed a lower proportion of MPE which accounted for the large percentages of intrathoracic metastatic lesions.40,41 The reason for the higher proportion of brain metastasis in the extrathoracic LT group is possibly due to wider options of local treatment modalities for a solitary metastatic lesion. While metastasectomy, SRS and SBRT are available modalities, strong evidences supporting LT on brain metastasis are also present.42–44 Furthermore, the intrathoracic LT group showed a significantly higher proportion of patients who underwent radiotherapy as the initial treatment. The majority of patients who underwent intrathoracic LT underwent radiotherapy for primary lung lesions. We assume that the squamous cell type, which was the frequent pathological type in the intrathoracic LT group, is more likely to be centrally located, and in some cases in which invasion of the central airway is present, radiotherapy to the intrathoracic lesion may have been required.45

The median OS in our study population was 8.8 months, which may be shorter than the result of a single extrathoracic metastatic NSCLC population from a Japanese study (15.2 months),46 but is similar to the median OS of the solitary single-organ metastases group from the pooled analysis of the Southwest Oncology Group mNSCLC protocols (8.7 months).18 It should be taken into consideration that a sizable number of patients from our study did not undergo active anticancer treatment, and after exclusion of this patient group, the median OS increased to 11.7 months.

An interesting finding in our study was that among the groups who underwent LT, T stage was found to be an independent predictor of OS, along with the ECOG and initial treatment modality. T stage has been described as a prognostic factor in several studies on oligometastasis.29,47 In a retrospective study of 29 patients with single-organ metastatic NSCLC, pathological T stage was shown to be a predictor of survival.47 Another retrospective study by Zhang et al. showed that smokers with T3/4 oligometastatic NSCLC did not benefit from LT.48 In the present study, the T3–4 stages showed significantly higher HR than the T1 stage in the multivariate analysis within the subgroup that underwent LT. It is necessary to evaluate the T stage components, whether the tumor size or the pattern of nearby organ invasion has a bigger role in the clinical impact. In a study by Jones et al., in which 11 patients with oligometastatic NSCLC were evaluated, the pathological primary tumor size was significantly associated with event-free survival and OS.77

There were notable differences between the long- and short-term survivor groups. The long-term survivor group showed a higher proportions of patients with pleural nodules and brain metastasis than the short-term survivor group. As a concurrent M1a finding, we speculated that pleural nodules are more indolent than other lesions such as MPE or malignant pericardial effusion. Furthermore, the long-term survivor group included a higher proportion of patients with brain metastasis. If untreated, brain metastasis is associated with poor prognosis; however, selected patients who present with synchronous brain-only oligometastatic lesion may have a better prognosis than other patients with brain metastases.49 In addition, local treatment of brain metastatic lesion with surgery or SRS has been proven effective.42

Despite some evidences supporting local treatment for oligometastatic sites in advanced NSCLC, clinicians should first examine several important factors. A meticulous multidisciplinary approach is necessary to determine whether oligometastatic patients will benefit from local treatment rather than suffer from unnecessary risks of possible adverse events. Clinicians should consider timing of the treatment, general conditions of patients, appropriate treatment modality and most importantly, safety issues regarding additional LT. Moreover, the management of oligometastatic NSCLC should be more personalized. Not only distant metastatic lesions, but other factors such as concurrent intrathoracic metastatic lesion should also be considered. Recent studies show diverse clinical approaches in advanced NSCLC such as primary tumor resection, hyperthermic intrathoracic chemotherapy in patients with malignant pleural effusion,50–52 and future studies that take various host and tumor-related factors into account are vital.

The present study had some limitations. First, PFS data were not described. We utilized a nationwide database that had strength in a number of study participants; however, the analysis of PFS was not possible. Second, due to the retrospective nature of the study, the evaluation of the clinical impact of LT may have been limited. The impact of LT in oligometastatic NSCLC has been discussed in a series of retrospective studies. Several prospective studies have been
conducted, but larger population studies are necessary, and they should have matching controls which consider tumor burden, performance scores and concurrent treatment modalities in order to estimate the size of any possible effect of LT on survival. Third, a sizable proportion of local radiotherapy performed in our patients may be palliative or to relieve the symptoms of the patients. Therefore, limitations in terms of assessing the impact are present. Fourth, for patients who repeatedly received LT, only the first-line of LT was described in the study. Finally, patients who underwent surgery as the initial treatment were included in the study. It is likely that patients with pathological upstaging of stage IV cancer after surgery were included.

In conclusion, the present study showed that in advanced NSCLC with a single extrathoracic metastatic lesion, LT, especially for curative purposes, has a significant association with OS. Moreover, among the patients who had undergone LT, factors such as the T stage, poor performance score, and initial treatment modality were significantly associated with OS. Future prospective studies including more detailed data on tumor burden and the treatment modalities are necessary to more actively perform LT in oligometastatic NSCLC.

ACKNOWLEDGMENTS
The data used for this study were provided by the Korean Association for Lung Cancer & Ministry of Health and Welfare, Korea Central Cancer Registry.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ORCID
Chang Dong Yeo https://orcid.org/0000-0002-4103-7921
Seung Joon Kim https://orcid.org/0000-0003-4836-8958

REFERENCES
1. Li D, Zhu X, Wang H, Qiu M, Li N. Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. J Thorac Dis. 2017;9:310–7.
2. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007;57:253–60.
3. Kim HC, Jung CY, Cho DG, Lee JE, Ahn JS, Kim SJ, et al. Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide lung cancer registry. Tuberc Respir Dis (Seoul). 2019;82:118–25.
4. Mok TS, Wu YL, Thongprasert S, Yang C-H, Chiu D-T, Saji N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.
6. Wu YL, Zhou C, Liang CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26:1883–9.
7. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
8. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
9. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England). 2016;387:1540–50.
10. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England). 2017;389:255–65.
11. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.
12. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
13. Rusthoven CG, Yeh N, Gaspar LE. Radiation therapy for Oligometastatic non-small cell lung cancer: theory and practice. Cancer. 2015;21:404–12.
14. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for Oligometastatic lung cancer. Front Oncol. 2017;7:210.
15. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;89:880–7.
16. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.
17. Jones GD, Lengel HB, Hsu M, Tan KS, Caso R, Ghanie A, et al. Management of synchronous extrathoracic oligometastatic non-small cell lung cancer. Cancers (Basel). 2021;13:1983.
18. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience. J Clin Oncol. 1991;9:1618–26.
19. Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, et al. Efficacy of local consolidative therapy for Oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20:e81–90.
20. Friedes C, Mai N, Hazell S, Fu W, Han P, Bowers M, et al. Consolidative radiotherapy in oligometastatic lung cancer: patient selection with a prediction nomogram. Clin Lung Cancer. 2020;21:e622–32.
21. Elaminy YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, et al. Local consolidation therapy (LCT) after first-line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2019;20:43–7.
22. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.
23. Liao Y, Fan X, Wang X. Effects of different metastasis patterns, surgery and other factors in the prognosis of patients with stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results (SEER) linked database analysis. Oncol Lett. 2019;18:581–92.
24. Buglione M, Jereczek-Fossa BA, Boni ML, Franceschini D, Fodor A, Zanetti IB, et al. Radiosurgery and fractionated stereotactic radiosurgery in oligometastatic/oligoprogressive non-small cell lung cancer patients: results of a multi-institutional series of 198 patients treated with “curative” intent. Lung Cancer. 2020;141:1–8.
25. Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019;51:1400–10.
26. Kim HC, Ji W, Lee JC, et al. Prognostic factor and clinical outcome in stage III non-small cell lung cancer: a study based on real-world clinical data in the Korean population. Cancer Res Treat. 2021;53:1033–41.
27. Lee SY, Hong YK, Ji W, Lee JC, Choi CM. Active treatment improves overall survival in extremely older non-small cell lung cancer patients: a multicenter retrospective cohort study. Cancer Res Treat. 2021;53:104–11.
28. Haussmann J, Matuschek C, Bölke E, Orth K, Ghadjar P, Budach W. The role of local treatment in Oligometastatic and Oligoprogressive cancer. Dtsch Arztebl Int. 2019;116:849–56.
29. Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Zhang J, Sepesi B, Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, et al. Report
30. Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D, et al. Continued EGFR–ALK-targeted therapy improves overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2020;21(37–46):e37.
31. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Improved overall survival with comprehensive local consolidative therapy for patients with oligometastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:173501.
32. Remon J, Menis J, Levy A, De Ruyscher DKM, Hendriks LEL. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2021;10:3486–502.
33. De Ruyscher D, Wanders R, Hendriks LE, van Baardwijk A, Meyers J, Houbrechts R, et al. Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous Oligometastases treated in a prospective phase II trial (NCT 01828450). J Thorac Oncol. 2018;13:1958–65.
34. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393:2051–8.
35. Mielgo-Rubio X, Garde-Noguera J, Juan O, Couanon F. Stereotactic body radiation therapy: a good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. World J Oncol. 2020;11:983–9.
36. Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13:1383–92.
37. Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D, et al. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment. Clin Transl Oncol. 2018;20:366–73.
38. Borghetti P, Bonù MI, Giubbolini R, Levra N’G, Mazzola R, Perna M, et al. Comcomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med. 2019;124:662–70.
39. Lim JU. Management of oligometastasis and Oligoprogression in patients with epidermal growth factor receptor mutation-positive NSCLC in the era of third-generation tyrosine kinase inhibitors. Clin Lung Cancer. 2021;21:e786–e792.
40. Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, et al. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018;52:1801254.
41. Dorrty M, Davidson K, Dash R, Jug R, Clarke JM, Nixon AB, et al. Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis. Transl Lung Cancer Res. 2021;10:2500–8.
42. Bai H, Xu J, Yang H, Jin B, Lou Y, Wu D, et al. Survival prognostic factors for patients with synchronous brain oligometastatic non-small cell lung carcinoma receiving local therapy. Onco Targets Ther. 2016;9:4207–13.
43. Nikitas J, Roach M, Robinson C, Bradley J, Huang J, Perkins S, et al. Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 2020;21:32–5.
44. Onesti CE, Iacono D, Angelini S, Lauro S, Mazzotta M, Occhipinti MA, et al. Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. Transl Lung Cancer Res. 2016;5:712–9.
45. Paris C, Benichou J, Saunier F, Metayer J, Brochard P, Thiberville L, et al. Smoking status, occupational asbestos exposure and bronchial location of lung cancer. Lung Cancer. 2003;40:17–24.
46. Sakai K, Kuramoto J, Kojima A, Nishimura H, Kuwabara Y, Toda M, et al. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. Int J Clin Oncol. 2019;24:1549–57.
47. Collaud S, Stahel R, Inci I, Hillinger S, Schneider D, Kestenholz P, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer. 2012;78:234–8.
48. Zhang JT, Liu SY, Yan HH, Wu YL, Nie Q, Zhong WZ. Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. BMC Cancer. 2019;19:1051.
49. Niibe Y, Chang YJ. Novel insights of oligometastases and oligorecurrence and review of the literature. Pulm Med. 2012;2012:261096.
50. Migliore M, Nardini M. Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion? Eur Respir Rev. 2019;28:190018.
51. Song K, Flores RM. A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer. Ann Transl Med. 2021;9:9558.
52. Li H, Liu T, Sun Z, Wang Z, Liu X, Yang F. New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature. Ann Transl Med. 2021;9:9559.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lim JU, Kang HS, Shin AY, Yeo CD, Park CK, Lee SH, et al. Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis. Thorac Cancer. 2022;13:1349–60. https://doi.org/10.1111/1759-7714.14398